Tag Archive for: Novo Holdings

Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors

/in

Tenmile and Novo Holdings are core investors Cristina Larkin, Bruce Montgomery, and Michael Lamprecht to join the Board of Directors Revagenix, Inc. is advancing a focused pipeline of antibiotic programs designed to treat infections caused by multidrug-resistant organisms SAN FRANCISCO, Jan. 5, 2024 – Revagenix, Inc., a biopharmaceutical company dedicated to the discovery and development of novel antibiotics, today announced […]

Read more

Optimum’s Year-End Review  

/in

2023 was an exciting year for Optimum’s clients who overcame many of the market challenges to make significant strides forward with their vital life sciences research. Here are some of the highlights from what has been an exceptionally busy and successful year.   M&A & deals Synaffix continued to build momentum – Lonza acquired the […]

Read more

Insights from Optimum’s 15th Annual Healthcare Investor Conference 2023

/in

Optimum Strategic Communications celebrated its 15th Annual Healthcare Investor Conference – marking its crystal anniversary – and what a sparkler it was! Optimism, preparation, and resilience, these were the key takeaways from our wonderful speakers on Wednesday 11 October at the Wellcome Trust. Check out our panel summaries below to learn more or to rediscover […]

Read more

MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus

/in

New investment from EQT Life Sciences and OrbiMed with participation from existing investors MinervaX will hold financial reserves of more than €125 million, following the financing The financing supports the Company’s efforts to commence a Phase III clinical trial of its Maternal Vaccine against Group B Streptococcus Copenhagen, Denmark, 11 October 2023 – MinervaX ApS, a […]

Read more

Acesion Pharma Closes Oversubscribed €45M Series B Financing Round

/in

Financing co-led by new investors Canaan and Alpha Wave, and with participation by the Global BioAccess Fund and existing investor Novo Holdings Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces that it has successfully closed an […]

Read more